Drug attitude—DAI · patients with schizophrenia or related psychoses
1 finding from 1 review
Patient outcome: Quality of life · patients with schizophrenia or related psychoses
1 finding from 1 review
Process outcome, Practitioner Impact 3. Staff not trained (as suggested by the guideline) · patients with schizophrenia or related psychoses
Re‐written guideline text showed no clear difference in process outcome, Practitioner Impact 3. Staff not trained (as… compared with original guideline text (low certainty).
1 finding from 1 review
Process outcome, Practitioner Impact 4. Staff not supervised (as suggested by the guideline) · patients with schizophrenia or related psychoses
Re‐written guideline text showed no clear difference in process outcome, Practitioner Impact 4. Staff not supervised (as… compared with original guideline text (low certainty).
1 finding from 1 review
Specific behaviour: aggression ‐ important decrease in aggression · people with long‐term aggression in psychosis
HALOPERIDOL leads to lower specific behaviour: aggression ‐ important decrease in aggression compared with OTHER ANTIPSYCHOTICS (high certainty).
1 finding from 1 review
no estimate extracted
83 participants
High
Repeated need for rapid tranquillisation · people with long‐term aggression in psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour ‐ threat or injury to self or others average change score (ABS, high = worse) at 2 hours · people with long‐term aggression in psychosis
HALOPERIDOL leads to lower specific behaviours ‐ threat or injury to others/self compared with OTHER ANTIPSYCHOTICS (high certainty).
1 finding from 1 review
no estimate extracted
83 participants
High
Adverse effects ‐ any serious, specific adverse effects · people with long‐term aggression in psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcomes ‐ overall improvement · people with long‐term aggression in psychosis
HALOPERIDOL leads to lower global outcomes ‐ overall improvement compared with OTHER ANTIPSYCHOTICS (high certainty).
1 finding from 1 review
no estimate extracted
83 participants
High
Leaving the study early · people with long‐term aggression in psychosis
HALOPERIDOL showed no clear difference in leaving the study early compared with OTHER ANTIPSYCHOTICS (low certainty).
1 finding from 1 review
Economic outcomes · people with long‐term aggression in psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia
CHLORPROMAZINE may leads to higher no significant clinical response: short term (up to 6 months) compared with OLANZAPINE (low certainty).
1 finding from 1 review
QoL · patients with schizophrenia
1 finding from 1 review
Leaving the study early ‐ due to adverse effects (short term) · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to adverse effects ‐ short term (up to 6… compared with RISPERIDONE (very low certainty).
1 finding from 1 review
Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia
CHLORPROMAZINE showed no clear difference in no significant clinical response: short term (up to 6 months) compared with QUETIAPINE (moderate certainty).
1 finding from 1 review
Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · patients with schizophrenia
1 finding from 1 review
Quality of life: 1a. Average endpoint scores on various scales (MSQoL‐54, high = good) ‐ short term · patients with schizophrenia
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
CHLORPROMAZINE may leads to higher adverse effects: any observed extrapyramidal symptoms ‐ short term… compared with QUETIAPINE (low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
CHLORPROMAZINE showed no clear difference in leaving the study early due to any reason short term (up to 6 months) compared with QUETIAPINE (moderate certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes relapse: long term (over 12 months) compared with OLANZAPINE (very low certainty).
1 finding from 1 review